Page 225 - FBL AR 2019-20

CORPORATE STATUTORY FINANCIAL
OVERVIEW STATEMENTS STATEMENTS

Notes to the Consolidated financial statements for the year ended March 31, 2020

48 Related parties disclosures as per Ind AS 24 (contd.)
( H in Lakhs )
March 31, 2020 March 31, 2019
i. Other financial liabilities (Interest accrued but not due)
Holding company
DVK Investments Private Limited - 38.79
j. Provision for share of loss in a joint venture in excess of cost of investment
Joint venture
Agastya Films LLP 5.97 5.97

49 During the previous year ended March 31, 2019, the Parent Company sold 45,186 equity shares of H10 each in Zela Wellness Private
Limited (Zela). Consequently, the Company’s equity holding in Zela Wellness Private Limited (Zela) is reduced to 16.59% as against earlier
29.5% and accordingly, post November 29, 2018, the entity is not an associate of the Company.
50 Research and development expenditure:
Research and development expenditure of H653.85 Lakhs (March 31, 2019: H879.10 Lakhs) (excluding interest and depreciation) has
been charged to the Consolidated statement of profit and loss. The capital expenditure in the current year on research and development
amounts to H497.20 Lakhs (March 31, 2019: H115.16 Lakhs).
51 During the year ended March 31, 2020, Commission of H248.00 Lakhs to the Managing Director and Executive Directors and directors
sitting fees and commission to non-executive directors aggregating H73.34 Lakhs has been charged to the Consolidated statement of
profit and loss. During the year ended March 31, 2019, Commission of H1,137.54 Lakhs to the Managing Director and Executive Director
of Erstwhile Fermenta Biotech Limited and Commission and directors sitting fees aggregating H169.98 Lakhs to the Non-Executive
directors has been charged to the Consolidated statement of profit and loss

52 Categories of the financial instruments
( H in Lakhs )
Particulars March 31, 2020 March 31, 2019
Financial assets
Financial assets measured at fair value through Other comprehensive income
Investments in equity instruments - quoted 21.49 10.14
Investments in equity instruments - unquoted 4.11 48.05
Financial assets measured at fair value through profit or loss
Investments in mutual funds - unquoted - 114.79
Financial assets measured at amortised cost
(i) Trade receivables 6,977.42 6,554.40
(ii) Cash and cash equivalents 751.45 4,076.50
(iii) Bank balances other than (ii) above 2,559.54 5,036.92
(iv) Share application money - 597.00
(v) Loans 2,155.00 1,205.58
(vi) Other financial assets 1,042.95 720.97
Total Financial assets 13,511.96 18,364.35
Financial liabilities measured at amortised cost
(i) Borrowings 22,029.02 20,869.51
(ii) Lease liabilities 368.91 -
(iii) Trade payables 5,633.47 4,271.97
(iv) Other financial liabilities 1,616.15 3,109.75
Total Financial liabilities 29,647.55 28,251.23
53 Reconciliation of Level 3 fair value measurements:

Particulars March 31, 2020 March 31, 2019
Opening balance 48.05 4.11
Transferred during the year - 43.94
Total gains or (losses)
Recognised in consolidated statement of profit and loss. (43.94) -
Closing balance 4.11 48.05

223